Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EBT: 2010-2024

Historic EBT for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to -$22.2 million.

  • Ani Pharmaceuticals' EBT rose 207.31% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 773.73%. This contributed to the annual value of -$22.2 million for FY2024, which is 211.78% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBT of -$22.2 million as of FY2024, which was down 211.78% from $19.9 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year EBT high stood at $19.9 million for FY2023, and its period low was -$62.7 million during FY2022.
  • Moreover, its 3-year median value for EBT was -$22.2 million (2024), whereas its average is -$21.7 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' EBT plummeted by 922.36% in 2020 and then soared by 131.71% in 2023.
  • Ani Pharmaceuticals' EBT (Yearly) stood at -$26.0 million in 2020, then slumped by 115.92% to -$56.1 million in 2021, then dropped by 11.79% to -$62.7 million in 2022, then skyrocketed by 131.71% to $19.9 million in 2023, then crashed by 211.78% to -$22.2 million in 2024.